Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook

January 7, 2024

https://www.globenewswire.com/news-release/2024/01/07/2805020/15991/en/Amicus-Therapeutics-Reports-Preliminary-2023-Revenue-and-Provides-2024-Strategic-Outlook.html

2023 Total Revenue of ~$399.4M, a 21% Increase Year-Over-Year

>2,400 People Living with Fabry Disease on Galafold® Following a Year of Increased Demand

Read more at globenewswire.com

Related news for (FOLD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.